AGPS and neoplasm: The value of nivolumab clearance, which drives its plasma exposure, is the sum of the clearance in the tumor (target-mediated or proteolytic) [21], the hydrolytic clearance in other organs, and marginally, the clearance related to anti-drug antibodies (ADAs) [22] (Figure 5).